| Pantoprazole: a proton pump inhibitor. | |
| | |
MedLine Citation:
|
PMID: 19938880 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Pantoprazole is a proton pump inhibitor (PPI) that binds irreversibly and specifically to the proton pump, thereby reducing gastric acid secretion. Pantoprazole has a relatively long duration of action compared with other PPIs, and a lower propensity to become activated in slightly acidic body compartments. To date, no drug-drug interactions have been identified with pantoprazole in numerous interaction studies. Overall, in the short-term (8-10 weeks) initial treatment of gastro-oesophageal reflux disease (a condition that occurs when the reflux of gastric contents causes troublesome symptoms and/or complications) and long-term (6-24 months) maintenance therapy, oral pantoprazole 20 or 40 mg/day demonstrated similar efficacy to omeprazole, lansoprazole and esomeprazole and greater efficacy than histamine type 2 receptor antagonists. Pantoprazole is also effective in treating and preventing NSAID-related gastric and gastroduodenal injury. The optimal adult oral dose for gastric acid-related disorders is pantoprazole 40 mg once daily. Although data are limited, pantoprazole 20 or 40 mg/day was effective and well tolerated in the treatment of acid-related disorders in children and adolescents. Pantoprazole was also well tolerated in adults with acid-related disorders in short- and long-term studies. Thus, pantoprazole is a valuable agent for the management of acid-related disorders. |
| | |
Authors:
|
Luis Moreira Dias |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Clinical drug investigation Volume: 29 Suppl 2 ISSN: 1173-2563 ISO Abbreviation: Clin Drug Investig Publication Date: 2009 |
Date Detail:
|
Created Date: 2009-11-26 Completed Date: 2010-03-12 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9504817 Medline TA: Clin Drug Investig Country: New Zealand |
Other Details:
|
Languages: eng Pagination: 3-12 Citation Subset: IM |
Affiliation:
|
M?dico Gastroenterologista, Porto, Portugal. l.md@clix.pt |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
2-Pyridinylmethylsulfinylbenzimidazoles
/
adverse effects,
pharmacokinetics,
pharmacology,
therapeutic use* Anti-Inflammatory Agents, Non-Steroidal / adverse effects Anti-Ulcer Agents / adverse effects, pharmacokinetics, pharmacology, therapeutic use* Drug Interactions Gastroesophageal Reflux / drug therapy* Humans Peptic Ulcer / chemically induced, drug therapy, prevention & control Proton Pump Inhibitors / adverse effects, pharmacokinetics, pharmacology, therapeutic use* Recurrence / prevention & control |
| Chemical | |
Reg. No./Substance:
|
0/2-Pyridinylmethylsulfinylbenzimidazoles; 0/Anti-Inflammatory Agents, Non-Steroidal; 0/Anti-Ulcer Agents; 0/Proton Pump Inhibitors; 102625-70-7/pantoprazole |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Temporal Proteomic Analysis Reveals Continuous Impairment of Intestinal Development in Neonatal Pigl...
Next Document: Severe Gastro-oesophageal Reflux Disease.